August 2012
-
Sunovion is presenting observational study data at the Hospital Medicine 2016 conference showing that a substantial number of COPD patients are discharged from hospitals with a prescription for a dry powder inhaler despite their inability… Read more . . .
-
Boehringer Ingelheim has presented data at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting showing that the Spiriva Respimat tiotropium bromide soft mist inhaler improves lung function and reduces exacerbations when… Read more . . .
-
Powder testing specialist Freeman Technology has announced that Managing Director Tim Freeman has received the Richard S. Ladd Standards Development Award from the ASTM for development of ASTM Standard Designation D7891 “Standard Test Method for… Read more . . .
-
Australian medical cannabis company MGC Pharmaceuticals has signed a collaboration agreement with Israeli device developer SipNose for development of a cannabinoid therapy for the treatment of epilepsy, the company said. The agreement includes an option… Read more . . .
-
A study published in the British Journal of General Practice titled “Overdiagnosis of asthma in children in primary care: a retrospective analysis” found that over half of children diagnosed with asthma at several major healthcare… Read more . . .
-
Savara Pharmaceuticals has announced the completion of a $20 million financing round to fund a pivotal Phase 3 clinical trial of its AeroVanc vancomycin DPI for the treatment of MRSA lung infections in cystic fibrosis… Read more . . .
-
Intranasal delivery specialist Impel NeuroPharma and the Toronto-based Centre for Addiction and Mental Health (CAMH) have signed a licensing agreement for an intranasal neuropeptide-based therapy for the treatment of depression. The peptide, which was discovered… Read more . . .
-
Inhaled drug developer Alexza Pharmaceuticals has signed a non-binding letter of intent and entered into discussions with Grupo Ferrer regarding Ferrer’s acquisition offer, the company said. Alexza noted that the letter of intent allows the… Read more . . .
-
MannKind Corporation has announced the death of founder and Chairman Emeritus Alfred Mann at age 90, one week after he stepped down as Chairman of the Board. Mann served as CEO from November 2003 until… Read more . . .
-
Norwegian CDMO Curida, which offers a wide range of analytical, development, and manufacturing services for OINDPs, has announced a new strategic partnership with pharmAccel Consulting Director René Bommer. In July 2015, Curida acquired a nasal… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland